J&J in Talks to Sell DePuy Synthes to Apollo for $20 Billion

Johnson & Johnson (J&J) is in discussions to sell its orthopedics and neurosurgery subsidiary DePuy Synthes to private equity firm Apollo Global Management for approximately $20 billion. According to sources close to the matter, negotiations between the parties have not yet concluded and it remains uncertain whether a deal will be reached. The potential sale is seen as part of J&J's strategy to reshape its medical device portfolio. DePuy Synthes is a unit that offers orthopedic solutions such as hip and knee replacements, spinal implants, and trauma products. By divesting this unit, the company may aim to focus on pharmaceuticals and medical technology areas with higher growth potential. For Apollo Global Management, such an acquisition presents an opportunity to expand its presence in the healthcare sector. Private equity firms are showing interest in medical device businesses with stable cash flow and long-term growth expectations. A $20 billion valuation would be one of the largest transactions in the sector. If the deal is completed, it could provide a significant cash inflow to J&J's balance sheet, and the company could use this resource for debt reduction, dividend increases, or strategic investments. However, it is noted that negotiations are at an early stage and a definitive agreement is not guaranteed. Not investment advice.